Source: International Congress 2017 – NICU/ PICU: evaluating short- and long-term ventilatory management
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Torrent Vernetta (Castelldefels (Barcelona), Spain). Experience with subcutaneous treprostinil in children with pulmonary arterial hypertension. 2080

Member's Comments

No comment yet.

Related content which might interest you: Experience with inhaled iloprost in paediatric pulmonary arterial hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 Long-term continuous subcutaneous treprostinil therapy for pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 461s Year: 2003 Parenteral treprostinil for significant pulmonary arterial hypertension associated with pulmonary fibrosis: A safety study Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Safety and tolerability of rapid dose-titration of subcutaneous (SC) treprostinil in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Risk assessment and prognosis in patients with pulmonary arterial hypertension receiving intravenous treprostinil Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 Low dose intravenous iloprost therapy in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006 Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Intravenous iloprost for pulmonary arterial hypertension: still waiting for evidence Source: Eur Respir J 2009; 34: 7-9 Year: 2009 Broviac catheter complications of intravenous epoprostenol therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 636s Year: 2004 Inhaled iloprost in HIV-related pulmonary arterial hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004 Effect of intravenous epoprostenol on quality of life in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 563s Year: 2003 Pulmonary rehabilitation in patients with pulmonary arterial hypertension Source: ERS Course 2017 Year: 2017 Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Successful artocoronary bypass grafting in a patient with severe idiopathic pulmonary arterial hypertension: use of intravenous treprostinil Source: Eur Respir J 2006; 28: Suppl. 50, 384s Year: 2006 Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Effects of nebulised iloprost on pulmonary function and oxygenation in patients with severe pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 370s Year: 2002